Infectious Mononucleosis: The Humoral Response

  • Gary R. Pearson
Part of the Clinical Topics in Infectious Disease book series (CLIN.TOP.INFECT)


Infectious mononucleosis (IM) is characterized as an acute, usually self-limited, lymphoproliferative disorder caused by the Epstein-Barr virus (EBV) (Henle, Henle, and Diehl 1968; Henle and Henle 1978). During the course of this disease, antibodies are produced against a variety of antigens, some of which are synthesized during the virus replication cycle, while others are related to normal cellular elements. The antibodies produced against this latter category of antigens often have the characteristics of autoantibodies. Some of the antibodies produced during the course of IM are of significant diagnostic value for this disease, and others are produced probably as a consequence of EBV infection of B lymphocytes, the target cells for this virus (Pattengale, Smith, and Gerber 1974), and are of no apparent diagnostic or prognostic importance. They may, however, contribute to the development of the various complications frequently noted following the active disease.


Lymphoblastoid Cell Line Infectious Mononucleosis Cold Agglutinin Early Antigen Convalescent Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ajdukiewicz, A., Dudley, F., Fox, R.A., Sherlock, S., and Doniach, D. (1972). Immunological studies in an epidemic of infective hepatitis. Lancet 1:803–806.PubMedCrossRefGoogle Scholar
  2. Andersen, P., and Faber, V. (1978). Antibodies to smooth muscle and other tissue components in infectious mononucleosis. Scand. J. Infect. Dis. 10:1–5.PubMedGoogle Scholar
  3. Barrett, A.M. (1941). The serological diagnosis of glandular fever.J. Hyg. 41:330–343.CrossRefGoogle Scholar
  4. Bender, C.E. (1958). Interpretation of hematologic and serologic findings in the diagnosis of infectious mononucleosis. Ann. Intern. Med. 49:853–865.Google Scholar
  5. Beer, P. (1936). The heterophile antibodies in infectious mononucleosis and after the injection of serum. J. Clin. Invest. 15:591–599.PubMedCrossRefGoogle Scholar
  6. Britton, S., Andersson-Anvret, M., Gergely, P., Henle, W., Jondal, M., Klein, G., Sandstedt, B., and Svedmyr, G. (1978). EB virus immunity and tissue distribution in a fatal case of infectious mononucleosis.N. Engl. J. Med. 298:89–92.PubMedCrossRefGoogle Scholar
  7. Carter, R.K. (1966). Antibody formation in infectious mononucleosis. 2. Other 19S antibodies and false- positive serology. Brit. J. Haemat. 12:268–275.PubMedCrossRefGoogle Scholar
  8. Davidsohn, I. (1938). Test for infectious mononucleosis.Am. J. Clin. Pathol. 8:56–60.Google Scholar
  9. Davidsohn, I., and Walker, P.H. (1935). The nature of heterophil antibodies in infectious mononucleosis. Am. J. Clin,. Pathol. 5:455–465.Google Scholar
  10. deSchryver, A., Klein G., Hewetson, J., Rocchi, G., Henle, W., Henle, G., Moss, D.J., and Pope, J.H. (1974). Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). Int. J. Cancer 13:353–362.CrossRefGoogle Scholar
  11. Elling, P., and Faber, V. (1968). Antinuclear antibodies in infectious mononucleosis. Lancet 1:918–919.PubMedCrossRefGoogle Scholar
  12. Evans, A.S., Niederman, J.C., Cenabre, L.C., West, B., and Richards, V.A. (1975). A prospective evaluation of heterophil and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody. J. Infect. Dis. 132:546–554.PubMedCrossRefGoogle Scholar
  13. Falk, L., Wolfe, L., Deinhardt, F., Paciga, J., Dombos, L., Klein, G., Henle, W., and Henle, G. (1974). Epstein-Barr virus transformation of non-human primate lymphocytes in vitro. Int. J. Cancer. 13:363–376.PubMedCrossRefGoogle Scholar
  14. Gerber, P. (1972). Activation of Epstein-Barr virus by 5-bromodeoxyuridine in “virus-free” human cells. Proc. Natl. Acad Sci. (USA) 69:83–85.CrossRefGoogle Scholar
  15. Gerber, P., and Deal, D.R. (1970). Epstein-Barr virus-induced viral and soluble complement-fixing antigens in Burkitt’s lymphoma cell cultures. Proc. Soc. Exp. Biol. Med. 134:748–751.PubMedGoogle Scholar
  16. Goldschmidts, W., Luka, J., and Pearson, G.R. (1987). A restricted component of the Epstein-Barr virus (EBV) early antigen complex is structurally related to ribonucleotide reductase.Virology 157:220–226.PubMedCrossRefGoogle Scholar
  17. Hampar, B., Derge, J.G., Martos, L.M., and Walter J.L. (1972). Synthesis of Epstein-Barr virus after activation of the virus genome in a “virus-negative” human lymphoblastoid cell (Raji) made resistant to 5-bromodeoxyuridine.Proc. Natl. Acad. Sci. (USA) 69:78–82.CrossRefGoogle Scholar
  18. Henle, G., and Henle, W. (1966). Immunofluorescence in cells derived from Burkitt’s lymphoma. J. Bact. 91:1248–1256.PubMedGoogle Scholar
  19. Henle, G., Henle, W., and Diehl, V. (1968). Relationship of Burkitt’s tumor associated herpes-type virus to infectious mononucleosis. Proc. Natl. Acad. Sci. (USA) 59:94–101.CrossRefGoogle Scholar
  20. Henle, G., Henle, W., and Horwitz, C.A. (1974). Antibodies to Epstein-Barr virus nuclear antigen in infectious mononucleosis.J. Infect. Dis. 130: 231–239.PubMedCrossRefGoogle Scholar
  21. Henle, G., Henle, W., and Klein, G. (1971). Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int. J. Cancer 8:272–278.PubMedCrossRefGoogle Scholar
  22. Henle, G., Lennette, E.T., Alspaugh, M.A., and Henle, W. (1979). Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus specific IgM antibodies. Clin. Exp. Immuno. 362:415–422.Google Scholar
  23. Henle, W., and Henle, G. (1978). The immunological approach to study of possible virus-induced human malignancies using the Epstein-Barr virus as example.Prog. Exp. Tumor Res. 21:19–48.PubMedGoogle Scholar
  24. Henle, W., and Henle, G. (1980). Consequences of persistent Epstein-Barr virus infections. In Viruses in Naturally Occurring Cancers, M. Essex, G. Todaro, and H. zur Hausen (eds.). Cold Spring Harbor Conferences on Cell Proliferation, Cold Spring Laboratory, vol. 7, pp. 3–10.Google Scholar
  25. Henle, W., Henle, G., Andersson, J., Emberg, I., Klein, G., Horwitz, C.A., Marklund, G., Rymo, L., Wellinder, C., and Straus, S.E. (1987). Antibody response to Epstein-Barr virus-determined antigen (EBNA)-l and EBNA-2 in acute and chronic Ep- stein-Barr virus infection. Proc. Natl. Acad. Sci. (USA) 84:570–574.CrossRefGoogle Scholar
  26. Henle, W., Henle, G., Niederman, J.C., Klemola, E., and Haltia, K. (1973). Antibodies to early antigens induced by the Epstein-Barr virus in infectious mononucleosis. J. Infect. Dis. 128:283–289.PubMedCrossRefGoogle Scholar
  27. Henle, W., Henle, G., Zajac, B.A., Pearson, G., Waubke, R., and Scriba, M. (1970). Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 169:188–190.PubMedCrossRefGoogle Scholar
  28. Hewetson, J.F., Bocker, J.F., Sereni, P., Rapp, C.E., and Henle, W. (1979). Development of antibodies reactive in antibody-dependent cellular cytotoxicity in infectious mononucleosis. Infect. Immunol. 24:121–126.Google Scholar
  29. Hewetson, J.F., Rocchi, G., Henle, W., and Henle, G. (1973). Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis. J. Infect. Dis. 128:283.PubMedCrossRefGoogle Scholar
  30. Hoagland, R.J. (1963). Resurgent heterophil antibody reaction after mononucleosis. N. Engl. J. Med. 269:1307–1309.PubMedCrossRefGoogle Scholar
  31. Hoffman, G.J., Lazarowitz, S.G., and Hayward, S.D. (1980). Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad Sci (USA) 77:2979–2983.CrossRefGoogle Scholar
  32. Holborow, E.J. (1972). Immunological aspects of viral hepatitis.Brit. Med. Bull. 28:142–144.PubMedGoogle Scholar
  33. Holborow, E.J., Asherson, G.L., Johnson, G.D., Barnes, R.D.S., and Carmichael, D.L. (1963). Anti-nuclear factor and other antibodies in blood and liver diseases. Brit. Med. J. 1:656–658.PubMedCrossRefGoogle Scholar
  34. Horwitz, C.A., Moulds, J., Henle, W., Henle, G., Po- lesky, H., Balfour, H.H., Jr., Schwartz, B., and Hoff, T. (1977). Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes.Blood 50:195–202.PubMedGoogle Scholar
  35. Hossaini, A.A. (1970). Anti-i in infectious mononucleosis. Am. J. Clin. Pathol. 53:198–203.PubMedGoogle Scholar
  36. Jenkins, W.J., Köster, H.G., Marsh, W.L., and Carter, R.L. (1965). Infectious mononucleosis: An unsuspected source of anti-i. Brit. J. Haemal 11:480–483.CrossRefGoogle Scholar
  37. Kano, K., and Milgram, F. (1977). Heterophil antigens and antibodies in medicine. Current Topics Microbiol. Immunol. 77:43–69.CrossRefGoogle Scholar
  38. Kaplan, M.E., and Tan, E.M. (1968). Antinuclear antibodies in infectious mononucleosis. Lancet 1:561–563.PubMedCrossRefGoogle Scholar
  39. Klein, G., Clifford, P., Klein, E., Smith, R.T., Minowada, J., Kourilsky, D.M., and Burchenal, J.H. (1967). Membrane immunofluorescence reactions of Burkitt’s lymphoma cells from biopsy specimens and tissue culture. J. Natl Cancer Inst. 39:1027–1044.PubMedGoogle Scholar
  40. Klein, G., Clifford, P., Klein, E., and Stjemsward, J. (1966). Search for tumor-specific immune reactions in Burkitt’s lymphoma patients by the membrane immunofluorescence reaction. Proc. Natl. Acad Sci. (USA) 55:1628–1635.CrossRefGoogle Scholar
  41. Klein, G., Person, G.R., Henle, W., Diehl, V., and Niederman, J.C. (1968). Relation between Epstein-Barr viral and cell membrane immunoflourescence in Burkitt tumor cells. 2. Composition of cells and sera from patients with Burkitt’s lymphoma and infectious mononucleosis. J. Exp. Med. 128: 1021–1030.PubMedCrossRefGoogle Scholar
  42. Klein, G., Svedmyr, E., Jondal, M., and Pearson, P.O. (1976). EBV-determined nuclear antigen (EBNA) positive cells in the peripheral blood of infectious mononucleosis patients. Int. J. Cancer. 17:21–26.PubMedCrossRefGoogle Scholar
  43. Langhome, J., and Feizi, T. (1977). Studies on the heterophile antibodies of infectious mononucleosis. 1. Separation of four antibody populations, none of which contains lymphocytotoxic activity. Clin. Exp. Immunol. 30:354–363.Google Scholar
  44. Lee, C.L., Davidson, I., and Slaby, R. (1968). Horse agglutinins in infectious mononucleosis. Am. J. Clin. Pathol. 49:3–11.PubMedGoogle Scholar
  45. Li, J-S., Zhow, B-S., Dutschman, G.E., Grill, S.P., Tan, R-S, and Cheng, Y-C. (1987). Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J. Virol. 61:2947–2949.PubMedGoogle Scholar
  46. Linder, E., Kurki, P., and Anderson, L.C. (1979). Autoantibody to intermediate filaments: in infectious mononucleosis.Clin. Immunol. Immunopath. 14:411–417.CrossRefGoogle Scholar
  47. Luka, J., Kreofsky, T., Pearson, G.R., Hennessy, K., and Kieff, E. (1984). Identification and characterization of a cellular antigen that cross reacts with the Epstein-Barr virus nuclear antigen. J. Virol. 52:833–838.PubMedGoogle Scholar
  48. Maeda, M., Sairenji, T., and Hinuma, Y. (1979). Reactivity of Paul-Bunnell type heterophil antibody in sera from infectious mononucleosis patients with the surface of lymphoid cells carrying Epstein-Barr virus genomes. Microbiol. Immunol. 1189–1197.Google Scholar
  49. Nikoskelainen, J., Neel, E.U., and Stevens, D.A. (1979). Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J. Clin. Microbiol. 10:75–79.PubMedGoogle Scholar
  50. North, J.R., Morgan, A.J., and Epstein, M.A. (1981). Observations on the EB virus envelope and virus- determined membrane antigen (MA) polypeptides. Int. J. Cancer 26:231–240.CrossRefGoogle Scholar
  51. Nyormoi, O., Thorley-Lawson, D.A., Elkington, J., and Strominger, J.L. (1976). Differential effect of phosphonoacetic acid on the expression of Epstein- Barr viral antigens and virus production.Proc. Natl. Acad. Sci. (USA) 73:1745–1748.CrossRefGoogle Scholar
  52. Pattengale, P.K., Smith, R.W., and Gerber, P. (1974). B cell characteristics of human peripheral and cord blood lymphocytes transformed by Epstein-Barr virus. J. Natl. Cancer Inst. 52:1081–1086.PubMedGoogle Scholar
  53. Paul, J.R., and Bunnell, W.W. (1932). Presence of heterophil antibodies in infectious mononucleosis. Am. J. Med Sci. 183:90–104.CrossRefGoogle Scholar
  54. Pearson, G.R. (1980). Epstein-Barr virus. Immunology. In Viral Oncology, G. Klein (ed.). New York, Raven Press, pp. 739–767.Google Scholar
  55. Pearson, G.R., Dewey, F., Klein, G., Henle, G., and Henle, W. (1970). Relation between neutralization of Epstein-Barr virus and antibodies to cell membrane antigens induced by the virus. J. Natl. Cancer Inst. 45:989–995.PubMedGoogle Scholar
  56. Pearson, G.R., Henle, G., and Henle, W. (1971). Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines. J. Natl. Cancer Inst. 46:1243–1250.PubMedGoogle Scholar
  57. Pearson, G.R., and Luka, J. (1986). Characterization of Epstein-Barr virus-determined antigens. In The Epstein-Barr Virus: Recent Advances, M.A. Epstein and B.G. Achong (eds.). London, William Heinemann Medical Books, pp. 47–74.Google Scholar
  58. Pearson, G.R., Luka, J., and Docherty, J. (1986). Monoclonal antibodies in the diagnosis of EBV-induced disease. In Human Herpesvirus Infections: Pathogenesis, Diagnosis and Treatment, C. Lopez and B. Roizman (eds.). New York, Raven Press, pp. 211–220.Google Scholar
  59. Pearson, G.R., Qualtiere, L.F., Klein, G., Norin, T., and Bal, I.S. (1979). Epstein-Barr virus-specific antibody-dependent cellular cytoxicity in patients with Burkitt’s lymphoma. Int. J. Cancer 24:402–406.PubMedCrossRefGoogle Scholar
  60. Qualtiere, L.F., and Pearson, G.R. (1979). Epstein-Barr virus-induced membrane antigens: Immunochemical characterizations of Triton X-100 solubilized viral membrane antigens from EBV superinfected Raji cells. Int. J. Cancer 23:808–817.PubMedCrossRefGoogle Scholar
  61. Qualtiere, L.F., and Pearson, G.R. (1980). Radioimmune precipitation study comparing the Epstein- Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA). Virology 102:360–369.PubMedCrossRefGoogle Scholar
  62. Qualtiere, L.F., Chase, E., Vroman, B., and Pearson, G.R. (1982). Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Proc. Natl. Acad. Sci. (USA) 79:616–620.CrossRefGoogle Scholar
  63. Reedman, B.M., and Klein, G. (1973). CeUular locaH- zation of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non- producer lymphoblastoid cell lines. Int. J. Cancer 2:499–520.CrossRefGoogle Scholar
  64. Rocchi, G., Hewetson, J., and Henle, W. (1973). Specific neutralizing antibodies in Epstein-Barr virus associated diseases. Int. J. Cancer 11:637–647.PubMedCrossRefGoogle Scholar
  65. Rosenfield, R.E., Schmidt, P.J., Calvo, R.C., and McGinnis, M.H. (1965). Anti-i, a frequent cold agglutinin in infectious mononucleosis. Vox Sang 10:631–634.PubMedCrossRefGoogle Scholar
  66. Shope, T., and Miller G. (1973). Epstein-Barr virus: Heterophil responses in squirrel monkeys inoculated with virus-transformed autologous leukocytes. J. Exp. Med. 137:140–147.PubMedCrossRefGoogle Scholar
  67. Stuart, C.A., Grifin, A.M., Wheeler, K.M., and Batty, S. (1936). A thermostable antigen in beef calls. Proc. Soc. Exp. Biol. 34:212–215.Google Scholar
  68. Summers, W.C., and Klein, G. (1976). Inhibition of EBV DNA synthesis and late gene expression by phosphonoacetic acid. J. Virol. 18:151–155.PubMedGoogle Scholar
  69. Sutton, R.N.P., Edmond, R.T.D., Thomas, D.B., and Doniach, D. (1974). The occurrence of autoantibodies in infectious mononucleosis. Clin. Exp. Immunol. 17:427–436.PubMedGoogle Scholar
  70. Svedmyr, A., Demissie, A., Klein, G., and Clifford, P. (1970). Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with the Epstein-Barr virus. J. Natl. Cancer Inst. 44:595–610.PubMedGoogle Scholar
  71. Thomas, B.D. (1972). Antibodies to membrane antigen(s) common to thymocytes and a subpopulation of lymphocytes in infectious mononucleosis.Lancet 1:399–403.PubMedCrossRefGoogle Scholar
  72. Thorley-Lawson, D.A., and Edson, C.M. (1979). Polypeptides of the Epstein-Barr virus membrane antigen complex. J. Virol. 32:458–467.PubMedGoogle Scholar
  73. Thorley-Lawson, D.A., and GerHnger, K. (1980). Monoclonal antibodies against the major glycoprotein (gp 350/220) of Epstein-Barr virus neutralize infectivity. Proc. Natl. Acad. Sci. (USA) 77: 5307–5311.CrossRefGoogle Scholar
  74. Virelizier, J.L., Lenoir, G., and Griscelli, C. (1978). Persistent Epstein-Barr virus infection with a child with hypergammaglobulinemia and immunoblastic proliferation associated with a selected defect in immune interferon secretion. Lancet 2:231–234.PubMedCrossRefGoogle Scholar
  75. Vonka, V., Benyesh-Melnick, M., and McCombs, R.J. (1970). Antibodies in human sera to soluble and viral antigens found in Burkitt’s lymphoma and other lymphoblastoid cell lines. J. Natl. Cancer Inst. 44:865–872.PubMedGoogle Scholar
  76. Whitehouse, J.M.A., Ferguson, N., and Currie, G.A. (1974). Autoantibody to microtubules in infectious mononucleosis. Clin. Exp. Immunol. 17:227–235.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Gary R. Pearson

There are no affiliations available

Personalised recommendations